VCM
SLS icon

Versant Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Versant Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.61K Buy
+131
New +$1.64K ﹤0.01% 2632

Other funds holding SLS

EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.51B AUM 33.52% 1-Year Est. Return
RI
Ridgewood Investments Springfield, New Jersey $271M AUM
FD
Financial Designs Claremont, California $194M AUM 10.52% 1-Year Est. Return
FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Versant Capital Management's SLS Position: Q3 2026 in Review

Versant Capital Management opened a new position in SELLAS Life Sciences (SLS) in Q3 2026: 131 shares worth $1.61K. The stake represents ﹤0.01% of the portfolio and ranks #2632 among its holdings.

13 funds tracked by Wall St. Rank hold SLS as of Q3 2026.

  • Versant Capital Management held 131 shares of SELLAS Life Sciences worth $1.61K as of Q3 2026.
  • SELLAS Life Sciences was a new Versant Capital Management position in Q3 2026.
  • SELLAS Life Sciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2632 holding.
  • 13 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.